Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3030% below fair value
$9.25−0.33 (-3.44%)
Close on Nov 17, 2026Market cap $1.57BP/E –Yield –
Vir Biotechnology cash
Cash and short-term investments held at the end of each period.
Vir Biotechnology's cash was $528.59M at Jun 30, 2026. For fiscal 2025 it was $460.94M, down 53.8% from the year before. The highest annual figure on record is $2.40B in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $460.94M | -53.8% |
| FY2024 | Dec 31, 2024 | $996.75M | -38.8% |
| FY2023 | Dec 31, 2023 | $1.63B | -32.1% |
| FY2022 | Dec 31, 2022 | $2.40B | +163.9% |
| FY2021 | Dec 31, 2021 | $909.50M | +23.4% |
| FY2020 | Dec 31, 2020 | $736.90M | +85.7% |
| FY2019 | Dec 31, 2019 | $396.92M | +260.2% |
| FY2018 | Dec 31, 2018 | $110.21M | -41.7% |
| FY2017 | Dec 31, 2017 | $188.92M | +1238.5% |
| FY2016 | Dec 31, 2016 | $14.11M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $528.59M | -11.7% |
| Q1 FY2026 | Mar 31, 2026 | $470.44M | -40.5% |
| Q4 FY2025 | Dec 31, 2025 | $460.94M | -53.8% |
| Q3 FY2025 | Sep 30, 2025 | $497.83M | -58.2% |
| Q2 FY2025 | Jun 30, 2025 | $598.75M | -58.1% |
| Q1 FY2025 | Mar 31, 2025 | $790.94M | -47.6% |
| Q4 FY2024 | Dec 31, 2024 | $996.75M | -38.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.19B | -30.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.43B | -24.7% |
| Q1 FY2024 | Mar 31, 2024 | $1.51B | -34.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.63B | -32.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.70B | -29.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.90B | -17.4% |
| Q1 FY2023 | Mar 31, 2023 | $2.30B | +64.3% |
| Q4 FY2022 | Dec 31, 2022 | $2.40B | +163.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.40B | +155.5% |
| Q2 FY2022 | Jun 30, 2022 | $2.30B | +162.3% |
| Q1 FY2022 | Mar 31, 2022 | $1.40B | +91.0% |
| Q4 FY2021 | Dec 31, 2021 | $909.50M | +23.4% |
| Q3 FY2021 | Sep 30, 2021 | $939.50M | +13.7% |
| Q2 FY2021 | Jun 30, 2021 | $876.70M | +58.7% |
| Q1 FY2021 | Mar 31, 2021 | $733.00M | +106.1% |
| Q4 FY2020 | Dec 31, 2020 | $736.90M | +85.7% |
| Q3 FY2020 | Sep 30, 2020 | $826.60M | +158.2% |
| Q2 FY2020 | Jun 30, 2020 | $552.40M | +584.7% |
| Q1 FY2020 | Mar 31, 2020 | $355.61M | +449.4% |
| Q4 FY2019 | Dec 31, 2019 | $396.92M | +260.2% |
| Q3 FY2019 | Sep 30, 2019 | $320.20M | +571.7% |
| Q2 FY2019 | Jun 30, 2019 | $80.68M | -57.3% |
| Q1 FY2019 | Mar 31, 2019 | $64.72M | +358.6% |
| Q4 FY2018 | Dec 31, 2018 | $110.21M | – |
| Q3 FY2018 | Sep 30, 2018 | $47.67M | – |
| Q4 FY2017 | Dec 31, 2017 | $188.92M | – |
| Q4 FY2016 | Dec 31, 2016 | $14.11M | – |
See a number that looks wrong?